A Comparison of the Use of Clinical-Guideline–Recommended Antihypertensive Regimens in Mexican American, Non-Hispanic Black, and Non-Hispanic White Adults With Type 2 Diabetes and Hypertension in the United States: NHANES 2003-2012. (December 2016)

• Record Type: Journal Article
• Authors: Perez, Alexandra; Levin, Andrea; Alam, Nowrin
• Is Part Of: Diabetes educator. Volume 42:Number 6(2016:Dec.)
• Page Start: 739
• Page End: 747
• Publication Date: 2016-12
• Subjects: Diabetes -- Study and teaching -- Periodicals; 616.462005
• DOI: 10.1177/0145721716666680
• Languages: English
• ISSNs: 0145-7217

Abstract

Purpose: The purpose of this study was to determine the use of clinical-guideline–recommended antihypertensive regimens among Mexican Americans (MAs) and non-Hispanic blacks and whites with type 2 diabetes and hypertension. Methods: A secondary data analysis based on National Health and Nutrition Examination Survey 2003-2012 cohort data included 1857 noninstitutionalized civilian MA, black, and white adults with type 2 diabetes and hypertension. Unadjusted and adjusted 2-way analysis of variance models evaluated whether there was a difference in the use of recommended antihypertensive regimens across race/ethnic group. Results: There was no difference in the use of recommended regimens across race/ethnic group (MAs, 79.1%; blacks, 81.7%; whites, 82.3%). Similarly, there was no difference between blood pressure goal levels and the use of recommended therapies across race/ethnicity ( P = .632). Mexican Americans were least likely and blacks most likely to be on 3 or more antihypertensive drug classes (16.8% vs 28%). Furthermore, MAs were least likely to be on recommended add-on therapies such as calcium channel blockers and diuretics. Conclusion: Racial/ethnic medication use disparities were observed when looking at the number of antihypertensive drug classes per patient regimen, and add-on therapy use was evaluated. Along with lifestyle modifications, frequent antihypertensive regimen reassessment is necessary.